Pay in 4 interest-free payments of $6.25 Learn more
Ships within 48 hours · Estimated delivery Aug 12 - Aug 17
References Jastreboff AM, et al, Triple-Hormone-Receptor Agonist Retatrutide for Obesity, a Phase 2 Trial, New England Journal of Medicine, 2023 Bajaj HS, et al, Efficacy and Safety of Retatrutide in Type 2 Diabetes, TRANSCEND-T2D-1, a Phase 3 Trial, The Lancet, 2026 Giblin K, Kaplan LM, Somers VK, et al, Retatrutide for the Treatment of Obesity, Obstructive Sleep Apnea and Knee Osteoarthritis, Rationale and Design of the TRIUMPH Registrational Clinical Trials, Diabetes, Obesity and Metabolism, 2026 ClinicalTrials.gov, TRIUMPH-1 trial registry entry, NCT05929066 Eli Lilly and Company, TRIUMPH-1 Phase 3 topline results announcement, May 2026 Eli Lilly and Company, TRIUMPH-4 Phase 3 trial results announcement, December 2025 Eli Lilly and Company, TRANSCEND-T2D-1 Phase 3 topline results announcement, March 2026 Central Drugs Standard Control Organisation, Subject Expert Committee meeting record on retatrutide Phase 3 trial permission, 2024 Medically reviewed by This guide was checked for medical accuracy by our review board before publishing
Foods Like White Rice, Toast, Oatmeal, Bananas, Applesauce, Soup, and Broth Are Easier for Your Stomach to Digest, Which Can Help You Avoid Diarrhea
GLP-1 also acts as a satiety signal by activating receptors on vagal afferent neurons that transmit signals from the gut to the hypothalamic satiety centers, including regions that regulate appetite, energy expenditure, and food reward
Some participants saw temporary increases in heart rate
A GLP-1 pill thats been approved in the US following successful studies, and is now awaiting UK approval
Stick to the approved sites and always ask your doctor if youre unsure
